Moderna (MRNA) Other Working Capital Changes (2018 - 2026)

Moderna (MRNA) has 9 years of Other Working Capital Changes data on file, last reported at -$54.0 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at -$54.0 million, down 17.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$161.0 million (down 1.9% YoY), and the FY2025 annual result was -$153.0 million, down 5.52% from the prior year.
• Other Working Capital Changes rose to -$54.0 million in Q1 2026 per MRNA's latest filing, from -$261.0 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $4.9 billion in Q4 2022 and troughed at -$2.4 billion in Q2 2022.
• A 5-year average of $198.8 million and a median of -$33.0 million in 2024 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes surged 225.55% in 2022, then sank 8090.0% in 2023.
• A 5-year view of Other Working Capital Changes shows it stood at $4.9 billion in 2022, then sank by 65.16% to $1.7 billion in 2023, then tumbled by 98.14% to $32.0 million in 2024, then plunged by 915.62% to -$261.0 million in 2025, then surged by 79.31% to -$54.0 million in 2026.
• Business Quant data shows MRNA's Other Working Capital Changes at -$54.0 million in Q1 2026, -$261.0 million in Q4 2025, and $40.0 million in Q3 2025.